Status:

UNKNOWN

Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

Lead Sponsor:

China National Center for Cardiovascular Diseases

Conditions:

Transcatheter Aortic Valve Replacement

Antithrombotic Therapy

Eligibility:

All Genders

18-85 years

Phase:

PHASE4

Brief Summary

This is a multicenter, open-label, randomized controlled study meant to test the superior efficacy of oral anticoagulation (OAC) therapy versus single antiplatelet therapy (SAPT) in patients after TAV...

Eligibility Criteria

Inclusion

  • Patients aged 18-85 years old with severe aortic stenosis;
  • Successful TAVR via femoral artery approach (VARC 3 device success criteria);
  • Implantation of self-expanding bioprosthetic valve;
  • Be willing to give informed consent.

Exclusion

  • Patients with anticoagulant indications, such as atrial fibrillation, intracardiac thrombosis, deep vein thrombosis, pulmonary embolism, history of mechanical valve implantation;
  • Patients needed double antiplatelet therapy, such as acute myocardial infarction within one year, coronary stent implantation within 6 months, peripheral artery stent implantation within 3 months;
  • Patients who received concomitant TAVR and percutaneous coronary intervention;
  • Patients with peptic ulcers or active bleeding or history of cerebral hemorrhage
  • Patients with ischemic stroke or TIA within 6 months;
  • Patients with left ventricular ejection fraction \< 30% or pulmonary hypertension (\>70mmHg) before discharge;
  • Patients intolerant or allergic to aspirin or Vitamin-K antagonists (warfarin);
  • Patients with evaluated glomerular filtration rate \<15ml/min/m2 (Cockcroft formula) or on dialysis;
  • Patients with poor compliance, unable to complete the study and follow-up as required;
  • Patients' life expectancy less than 1 year;
  • Patients who already participated in other clinical trials (within the last 30 days).

Key Trial Info

Start Date :

July 27 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

650 Patients enrolled

Trial Details

Trial ID

NCT05375474

Start Date

July 27 2023

End Date

December 31 2025

Last Update

October 23 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fuwai hospital

Beijing, Beijing Municipality, China, 100037